Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Neos Therapeutics Inc (NASDAQ: NEOS) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Neos Therapeutics Inc (NASDAQ: NEOS)  concerning whether a series of statements by Neos Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 19, 2015, Neos Therapeutics revealed that the U.S. Food and Drug Administration had identified deficiencies in the Company's new drug application for Cotempla XR-ODT that precluded discussion of labeling and marketing requirements at that time. 

Following this news, NASDAQ: NEOS dropped more than 23% during intraday trading on October 20, 2015. 

On August 11, 2016, the Company revealed its financial results for its second quarter of 2016, reporting it had missed its earnings expectations by $0.49 per share.

Following this news, NASDAQ: NEOS dropped $1.30, or 15.17%, to close at $7.27 on August 11, 2016.

Based in Grand Prairie, Texas, and founded in 2008 Neos Therapeutics Inc engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.

If you purchased shares of Neos Therapeutics Inc (NASDAQ: NEOS) you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185